Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | ATM | Q13315 | 1/20 | 0.52 |
| ▸ | TLR2 | O60603 | 1/20 | 0.51 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20394937 | 0.93 | ALDH1A1 (0.51) | RAB9ATLR2TLR1KMT2AMEN1 | |
| SCHEMBL3275575 | 0.88 | NPC1 (0.52) | NPC1RAB9AATMTLR2TLR1 | |
| SCHEMBL3380989 | 0.84 | KDM1A (0.51) | RAB9AALDH1A1SMN1; SMN2 | |
| SCHEMBL20394939 | 0.83 | PRMT5 (0.47) | NPC1RAB9AATMTLR2TLR1 | |
| SCHEMBL20236268 | 0.81 | SMN1; SMN2 (0.45) | NPC1KMT2AMEN1NAMPTALDH1A1 | |
| SCHEMBL20394970 | 0.81 | RAB9A (0.71) | NPC1RAB9AATMTLR2TLR1 | |
| SCHEMBL1710855 | 0.80 | SLC6A7 (0.53) | NPC1RAB9AATMTLR2TLR1 | |
| SCHEMBL20394940 | 0.77 | NAMPT (0.45) | NPC1RAB9AATMKMT2AMEN1 | |
| SCHEMBL20237203 | 0.76 | SMN1; SMN2 (0.41) | NPC1KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL302980 | 0.76 | NPC1 (0.48) | NPC1RAB9AATMKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2344456-B1 | NOVEL POTASSIUM CHANNEL BLOCKER | JAPAN TOBACCO INC (JP) | 2018-07-25 | — | — | EP | disclosed |
| US-8258138-B2 | Potassium channel blockers | XENTION LIMITED (GB) | 2012-09-04 | — | — | US | disclosed |
| US-20100087437-A1 | Novel Potassium Channel Blockers | XENTION LIMITED (GB) | 2010-04-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087437-A1 | Novel Potassium Channel Blockers | KCNB1, KCNJ2, KCNJ11 | NPC1 474/4885RAB9A 2125/4885ATM 4027/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.